secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001104659-24-056017
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed
--------------------------------------------------------------------------------

- Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).
- GAAP diluted EPS $0.78; non-GAAP adjusted diluted EPS $1.22 (+13% YoY); includes $0.05 IPR&D/milestone charge.
- Women's Health revenue +11% on Nexplanon (+34% ex-FX); Biosimilars +46% led by Hadlima ($30M vs $5M).
- Adjusted EBITDA $538M, margin 33.2%; full-year 2024 financial guidance ranges affirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/0001104659-24-056017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/tm2413293d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-056017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer